Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ABX-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : ABX-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABX-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : ABX-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABX-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : ABX-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Novotech
Deal Size : Inapplicable
Deal Type : Inapplicable